Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 13/1/2021
SIETES contiene 93213 citas

 1 a 20 de 173 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Torres A, Sibila O, Ferrer M, Polverino E, Menéndez R, Mensa J, Gabarrús A, Sellarés J, Restrepo MI, Anzueto A, Niederman MS, Agustí C. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 2015;313:677-86. [Ref.ID 98813]
2.Tiene citas relacionadas
Wunderink RG. Corticosteroids for severe community-acquired pneumonia: not for everyone. JAMA 2015;313:673-4. [Ref.ID 98812]
3.Tiene citas relacionadas
Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:565-71. [Ref.ID 93575]
4.Tiene citas relacionadas
Wenzel RP, Edmond MB. Septic shock - Evaluating another failed treatment. N Engl J Med 2012;366:2122-4. [Ref.ID 93042]
5.Tiene citas relacionadas Cita con resumen
Ranieri VM, Thompson BT, Barie PS, Dhainaut J-F, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khaldi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD, for the PROWESS-SHOCK Study Group. Drotecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055-64. [Ref.ID 93040]
7.Tiene citas relacionadas
Anónimo. Why do the results of randomised and observational studies differ?. BMJ 2011;343:1128. [Ref.ID 91915]
8. Cita con resumen
Mullard A. Drug withdrawal sends critical care specialists back to basics. Lancet 2011;378:1769. [Ref.ID 91834]
9.Tiene citas relacionadas
Emberson J, Bennett D, Parish S, Armitage J, Collins R, on behalf of the Heart Protection Study Collaborative Group. C-reactive protein in the Heart Protection Study. Authors' reply. Lancet 2011;377:1918-9. [Ref.ID 91291]
10.Tiene citas relacionadas
Ridker PM, Koenig W, Kastelein JJP. C-reactive protein in the Heart Protection Study. Lancet 2011;377:1918. [Ref.ID 91290]
11.Tiene citas relacionadas
C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ 2011;342:425. [Ref.ID 90228]
12.Tiene citas relacionadas Cita con resumen
Keavney B. C reactive protein and the risk of cardiovascular disease. BMJ 2011;342:393-4. [Ref.ID 90224]
14.Tiene citas relacionadas
Després J-P. CRP: star trekking the galaxy of risk markers. Lancet 2011;377:441-2. [Ref.ID 90199]
15. Cita con resumen
Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011;364:535-41. [Ref.ID 90172]
16.Tiene citas relacionadas
Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, Mora S, MacFadyen JG, Glynn RJ, Kastelein JJP, for the JUPITER Trial Study Group. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet 2010;376:333-9. [Ref.ID 89009]
17.Tiene citas relacionadas
Hausenloy DJ, Opie L, Yellon DM. Dissociating HDL cholesterol from cardiovascular risk. Lancet 2010;376:305-6. [Ref.ID 89001]
18. Cita con resumen
Anónimo. Rosuvastatina (Crestor) y riesgo de diabetes. PAM 2010;34:440-1. [Ref.ID 88966]
19. Cita con resumen
Ridker PM, Glynn RJ. JUPITER, rosuvastatin, and the European Medicines Agency. Lancet 2010;375:2071. [Ref.ID 88667]
Seleccionar todas
 1 a 20 de 173 siguiente >>